Isavuconazole in the Treatment of Invasive Aspergillosis and Mucormycosis Infections

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2016 Jun 23

PMID 27330318

Citations 32

Authors

Monica A Donnelley

Elizabeth S Zhu

George R Thompson 3rd

Affiliations

Soon will be listed here.

Abstract

We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole's broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy.

Citing Articles

Isavuconazole and Amphotericin B Synergic Antifungal Activity: In Vitro Evaluation on Pulmonary Aspergillosis Molds Isolates.

Calvo M, Lauricella F, Mellini A, Scalia G, Trovato L Antibiotics (Basel). 2024; 13(11).

PMID: 39596700 PMC: 11591417. DOI: 10.3390/antibiotics13111005.

Machine learning models to predict ligand binding affinity for the orexin 1 receptor.

Zhang V, OConnor S, Welsh W, James M Artif Intell Chem. 2024; 2(1).

PMID: 38476266 PMC: 10927255. DOI: 10.1016/j.aichem.2023.100040.

From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis.

Gulli S, Hallur V, Kale P, Menezes G, Russo A, Singla N Diagnostics (Basel). 2024; 14(3).

PMID: 38337830 PMC: 10855476. DOI: 10.3390/diagnostics14030314.

Synthesis of New Triazole-Based Thiosemicarbazone Derivatives as Anti-Alzheimer's Disease Candidates: Evidence-Based In Vitro Study.

Rahim F, Ullah H, Taha M, Hussain R, Sarfraz M, Iqbal R Molecules. 2023; 28(1).

PMID: 36615218 PMC: 9821906. DOI: 10.3390/molecules28010021.

Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents.

Hussain M, Ahmed S, Khan A, Siddiqui A, Khatoon S, Jahan S Eur J Med Chem. 2022; 246:115010.

PMID: 36566630 PMC: 9734071. DOI: 10.1016/j.ejmech.2022.115010.

References

Sathiapalan R, El-Solh H . Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol. 2002; 18(8):543-6. DOI: 10.1080/088800101753328529. View

Purkins L, Wood N, Kleinermans D, Nichols D . Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003; 56 Suppl 1:24-9. PMC: 1884319. DOI: 10.1046/j.1365-2125.2003.01995.x. View

Bates D, Yu D . Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barc). 2003; 39(10):801-13. DOI: 10.1358/dot.2003.39.10.799473. View

Steinbach W, Schell W, Blankenship J, Onyewu C, Heitman J, Perfect J . In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother. 2004; 48(5):1664-9. PMC: 400573. DOI: 10.1128/AAC.48.5.1664-1669.2004. View

Warn P, Sharp A, Denning D . In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother. 2005; 57(1):135-8. DOI: 10.1093/jac/dki399. View

Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T . Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in.... Antimicrob Agents Chemother. 2005; 50(1):279-85. PMC: 1346775. DOI: 10.1128/AAC.50.1.279-285.2006. View

Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E . Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2005; 50(1):286-93. PMC: 1346776. DOI: 10.1128/AAC.50.1.286-293.2006. View

Feldstein A, Smith D, Perrin N, Yang X, Simon S, Krall M . Reducing warfarin medication interactions: an interrupted time series evaluation. Arch Intern Med. 2006; 166(9):1009-15. DOI: 10.1001/archinte.166.9.1009. View

Chamilos G, Luna M, Lewis R, Bodey G, Chemaly R, Tarrand J . Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006; 91(7):986-9. View

10.

Eiden C, Peyriere H, Tichit R, Cociglio M, Amedro P, Blayac J . Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther. 2007; 32(3):321-4. DOI: 10.1111/j.1365-2710.2007.00812.x. View

11.

Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud J, Galperine T . Drug-drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf. 2007; 16(11):1227-33. DOI: 10.1002/pds.1473. View

12.

Gubbins P . Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients. Curr Opin Infect Dis. 2007; 20(6):579-86. DOI: 10.1097/QCO.0b013e3282f1be91. View

13.

Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-60. DOI: 10.1086/525258. View

14.

Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E . In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008; 52(4):1396-400. PMC: 2292541. DOI: 10.1128/AAC.01512-07. View

15.

De Pauw B, Walsh T, Donnelly J, Stevens D, Edwards J, Calandra T . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group.... Clin Infect Dis. 2008; 46(12):1813-21. PMC: 2671227. DOI: 10.1086/588660. View

16.

Thompson 3rd G, Fothergill A, Wiederhold N, Vallor A, Wickes B, Patterson T . Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother. 2008; 52(8):2959-61. PMC: 2493144. DOI: 10.1128/AAC.00646-08. View

17.

Andes D, Pascual A, Marchetti O . Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2008; 53(1):24-34. PMC: 2612175. DOI: 10.1128/AAC.00705-08. View

18.

Thompson 3rd G, Wiederhold N, Fothergill A, Vallor A, Wickes B, Patterson T . Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother. 2008; 53(1):309-11. PMC: 2612192. DOI: 10.1128/AAC.01216-08. View

19.

Majithiya J, Sharp A, Parmar A, Denning D, Warn P . Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother. 2008; 63(1):161-6. PMC: 2721698. DOI: 10.1093/jac/dkn431. View

20.

Gonzalez G . In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2008; 47(1):71-6. DOI: 10.1080/13693780802562969. View